Artikel ; Online: Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies.
Journal of microbiology (Seoul, Korea)
2022 Band 60, Heft 3, Seite(n) 238–246
Abstract: Middle East Respiratory Syndrome coronavirus (MERS-CoV), a contagious zoonotic virus, causes severe respiratory infection with a case fatality rate of approximately 35% in humans. Intermittent sporadic cases in communities and healthcare facility ... ...
Abstract | Middle East Respiratory Syndrome coronavirus (MERS-CoV), a contagious zoonotic virus, causes severe respiratory infection with a case fatality rate of approximately 35% in humans. Intermittent sporadic cases in communities and healthcare facility outbreaks have continued to occur since its first identification in 2012. The World Health Organization has declared MERS-CoV a priority pathogen for worldwide research and vaccine development due to its epidemic potential and the insufficient countermeasures available. The Coalition for Epidemic Preparedness Innovations is supporting vaccine development against emerging diseases, including MERS-CoV, based on platform technologies using DNA, mRNA, viral vector, and protein subunit vaccines. In this paper, we review the usefulness and structure of a spike glycoprotein as a MERS-CoV vaccine candidate molecule, and provide an update on the status of MERS-CoV vaccine development. Vaccine candidates based on both DNA and viral vectors coding MERS-CoV spike gene have completed early phase clinical trials. A harmonized approach is required to assess the immunogenicity of various candidate vaccine platforms. Platform technologies accelerated COVID-19 vaccine development and can also be applied to developing vaccines against other emerging viral diseases. |
---|---|
Mesh-Begriff(e) | Antibodies, Viral ; COVID-19 ; COVID-19 Vaccines ; Humans ; Middle East Respiratory Syndrome Coronavirus/genetics ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/genetics ; Viral Vaccines/genetics |
Chemische Substanzen | Antibodies, Viral ; COVID-19 Vaccines ; Spike Glycoprotein, Coronavirus ; Viral Vaccines ; spike protein, SARS-CoV-2 |
Sprache | Englisch |
Erscheinungsdatum | 2022-01-28 |
Erscheinungsland | Korea (South) |
Dokumenttyp | Journal Article ; Review |
ZDB-ID | 2012399-1 |
ISSN | 1976-3794 ; 1225-8873 |
ISSN (online) | 1976-3794 |
ISSN | 1225-8873 |
DOI | 10.1007/s12275-022-1547-8 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 5211: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.